SCHEMBL21963620

SCHEMBL21963620

COc1cc(C(=O)OCc2ccccc2)ccc1OC(=O)c1cccnc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.67
TDP1 Q9NUW8 3/20 0.67
LMNA P02545 1/20 0.67
ALDH1A1 P00352 2/20 0.58
MAPK1 P28482 2/20 0.58
MEN1 O00255 2/20 0.58
GAA P10253 2/20 0.58
KDM4E B2RXH2 1/20 0.58
HSP90AA1 P07900 1/20 0.53
AGTR1 P30556 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.51
USP2 O75604 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HDAC1 Q13547 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CYP3A4 P08684 2/20 0.49
MAPT P10636 1/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22015262 0.93 KMT2A (0.74) KMT2ATDP1LMNAALDH1A1MAPK1
SCHEMBL21963604 0.90 LMNA (0.69) KMT2ATDP1LMNAALDH1A1MAPK1
SCHEMBL21963579 0.88 KMT2A (0.69) KMT2ATDP1LMNAALDH1A1MAPK1
SCHEMBL21963593 0.88 LMNA (0.69) KMT2ATDP1LMNAALDH1A1MAPK1
SCHEMBL22015263 0.87 KMT2A (0.70) KMT2ATDP1LMNAALDH1A1MAPK1
SCHEMBL24195859 0.85 ALDH1A1 (0.56) KMT2ATDP1LMNAALDH1A1MAPK1
SCHEMBL21963621 0.84 MAPT (0.69) KMT2ATDP1LMNAALDH1A1MAPK1
SCHEMBL17769825 0.82 MAPT (0.61) KMT2ATDP1LMNAALDH1A1MAPK1
Benzyl Nicotinate SCHEMBL24600 0.82 LMNA (1.00) KMT2ATDP1LMNAALDH1A1MAPK1
Benzyl Nicotinate SCHEMBL29394048 0.82 LMNA (1.00) KMT2ATDP1LMNAALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220009892-A1 SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF INCILIA THERAPEUTICS PRIVATE LIMITED (IN) 2022-01-13 US disclosed
US-20220009892-A1 SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF INCILIA THERAPEUTICS PRIVATE LIMITED (IN) 2022-01-13 US disclosed
WO-2020100169-A1 SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF INCILIA THERAPEUTICS PRIVATE LIMITED (IN) 2020-05-22 WO disclosed
WO-2020100169-A1 SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF INCILIA THERAPEUTICS PRIVATE LIMITED (IN) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220009892-A1 SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF PC, PCCA, GLS2 KMT2A 2224/4885TDP1 4115/4885LMNA 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.